This five-part video series offers a comprehensive insight into the current treatment standards for muscle-invasive bladder cancer. Led by Prof. Dr. Günter Niegisch, Head of the Department of Conservative Urological Oncology at the Department of Urology at Düsseldorf University Hospital, the video series provides an overview of the current treatment landscape with practice-relevant knowledge.
The entire video series is based on the recently revised S3 guideline and covers the following topics:
Video 1 provides a general overview of current therapy for muscle-invasive bladder cancer. The individual pillars of therapy are then discussed in more detail. Episodes 2 and 3 deal with the current evidence for neoadjuvant and adjuvant therapy. Episode 4 provides more in-depth information on immunotherapy. And finally, the series ends in episode 5 with new data from the ESMO, including the NIAGARA study.
Overall, this five-part video series gives you an overview as well as specific information on all established and new MIBC treatment options and recommendations.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
This series was produced with the kind support of AstraZeneca.
At the end of this training you will know
- the current therapy for muscle-invasive bladder cancer
- the evidence for neoadjuvant and adjuvant therapy
- In-depth information on immunotherapy
- MIBC-relevant data from the ESMO, including the NIAGARA study
